- Report
- June 2024
- 209 Pages
Global
From €4040EUR$4,250USD£3,394GBP
- Report
- March 2025
- 194 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- May 2024
- 132 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- January 2025
- 182 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- August 2022
- 120 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- January 2022
- 200 Pages
Global
From €7130EUR$7,500USD£5,990GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- February 2024
- 180 Pages
Global
From €4724EUR$4,969USD£3,968GBP
- Report
- March 2020
- 49 Pages
Global
€1253EUR$1,318USD£1,053GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4706EUR$4,950USD£3,953GBP
- Report
- May 2021
Asia Pacific
From €3280EUR$3,450USD£2,755GBP
- Report
- March 2021
Global
From €4230EUR$4,450USD£3,554GBP
- Report
- April 2023
- 140 Pages
Global
From €4230EUR$4,450USD£3,554GBP
- Report
- September 2023
- 160 Pages
Global
From €3421EUR$3,599USD£2,874GBP
- Report
- June 2023
- 108 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- August 2023
- 479 Pages
Global
From €3394EUR$3,570USD£2,851GBP
- Report
- October 2022
- 310 Pages
Global
From €3651EUR$3,840USD£3,067GBP

The Irritable Bowel Syndrome (IBS) market is a subset of the Gastroenterology market. IBS is a chronic disorder of the digestive system that affects the large intestine. Symptoms include abdominal pain, bloating, constipation, and diarrhea. Treatment options include dietary changes, medications, and lifestyle modifications.
The IBS market is expected to grow due to increasing prevalence of the disorder, rising awareness of IBS, and the availability of new treatments. Additionally, the increasing demand for better diagnosis and treatment of IBS is expected to drive the market.
Some companies in the IBS market include Allergan, AstraZeneca, GlaxoSmithKline, Ironwood Pharmaceuticals, Novartis, Pfizer, Salix Pharmaceuticals, Shire, Sucampo Pharmaceuticals, and Takeda Pharmaceuticals. Show Less Read more